EUCTR2015-001183-19-ES进行中（未招募）不适用
enalidomide and dexamethasone (Ld) versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as initial therapy in Multiple Myeloma. - GEM-CLARIDEX
Fundación PETHEMA0 个研究点目标入组 306 人开始时间: 2015年7月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject must voluntarily sign and understand written informed consent.
- •2. Subject is ? 65 years at the time of signing the consent form.
- •3. Subject has histologically confirmed MM that has never before been treated, and according to the following definition of MM:
- •Clonal bone marrow plasma cells ? 10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:
- •1. Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:
- •- Hypercalcaemia: serum calcium > 0,25 mmol/L (> 1mg/dL) higher than the upper limit of normal or > 2,75 mmol/L (>11 mg/dL)
- •- Renal insufficiency: creatinine clearance < 40 mL per min or serum creatinine > 177 µmol/L (>2 mg/dL)
- •- Anaemia: haemoglobin value of > 20 g/L below the lower limit of normal, or a haemoglobin value < 100 g/L.
- •- Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT.
- •2. Any one or more of the following biomarkers of malignancy:
- •- Clonal bone marrow plasma cell percentage ? 60%
- •- Involved:uninvolved serum free light chain ratio ? 100
- •- > 1 focal lesions on MRI studies
- •4. Subject has no prior anti-myeloma treatment therapy within 14 days prior to initiation of study treatment except for corticosteroids with a maximum allowed dosage equivalent to three pulses of dexamethasone (40mg daily for 4 days equals one pulse).
- •5. Patients may have received prior adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care, or radiation therapy as palliation for pain and/or spinal cord compression
- •6. Subject has measurable disease as defined by > 0.5 g/dL serum monoclonal protein, > 10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, >0 .2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI.
- •7. Subject has a Karnofsky performance status ? 60% (> 50% if due to bony involvement of myeloma).
- •8. Subject is able to take prophylactic anticoagulation (patients intolerant to aspirin may use warfarin, acenocumarol or low molecular weight heparin).
- •9. If subject is a female of childbearing potential (FCBP), she must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 ? 14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with FCBP even if they have had a successful vasectomy.
- •10. Subject has a life expectancy ? 3 months
- •11. Subjects must meet the following laboratory parameters:
- •- Absolute neutrophil count (ANC) ? 1.0 x 10^9/L.
- •- Hemoglobin ? 7 g/dL.
- •- Platelet count ? 75.000/mm3 ( > 30 x 10^9/L if extensive bone marrow infiltration).
- •- Serum SGOT/AST < 3.0 x upper limits of normal (ULN).
- •- Serum SGPT/ALT < 3.0 x upper limits of normal (ULN).
- •- Serum total bilirubin < 2.0 mg/dL (3
排除标准
- •1. Subject has immeasurable MM (no measurable monoclonal protein, free light chains in blood or urine, or measureable plasmacytoma on radiologic scanning)
- •2. Subject has a prior history of other malignancies unless disease-free for ? 5 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or localized prostate cancer with Gleason score < 7 with stable prostate specific antigen (PSA) levels
- •3. Subject has had myocardial infarction within 6 months prior to enrollment, or NYHA (New York Hospital Association) Class III or IV heart failure (see Appendix VI), Ejection Fraction < 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, evidence of prolonged QTc interval in pre-treatment electrocardiogram, or active conduction system abnormalities
- •4. Female subject who is pregnant or lactating
- •5. Subject has known HIV infection
- •6. Subject has known active hepatitis B or hepatitis C infection
- •7. Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program
- •8. Subject is unable to reliably take oral medications
- •9. Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide
- •10. Subject has a history of thromboembolic event within the past 4 weeks prior to enrollment
- •11. Subject has any clinically significant medical or psychiatric disease or condition that, in the investigator?s opinion, may interfere with protocol adherence or a subject?s ability to give informed consent
- •12. Subject has previously been treated for MM
研究者
相似试验
进行中（未招募）
3 期
A clinical trial to study the effects of two drugs, Lenalidomide and Thalidomide given with low dose of Dexamethasone in patients with Multiple MyelomaCTRI/2015/06/005944Dr Reddys Laboratories Ltd
进行中（未招募）
1 期
enalidomide, Adriamycin, Dexamethasone (RAD)Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2009-016616-21-DEWuerzburg University Hospital470
进行中（未招募）
不适用
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failureThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-ATWilhelminen Krebsforschung GmbH50
进行中（未招募）
1 期
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure - LDThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-SKWilhelminen Krebsforschung GmbH50
进行中（未招募）
1 期
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failureThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-DEWilhelminen Krebsforschung GmbH50